{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-048873","form_type":"8-K","ticker":"CRSP","cik":"0001674416","company_name":"CRISPR Therapeutics AG","filed_at":"2026-02-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.854630+00:00","generated_at":"2026-05-16T03:03:39.140778+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"CRISPR Therapeutics Q4 2025 net loss $130.6M; CASGEVY Q4 revenue $54M, full year $116M","bullets":["Net loss of $130.6M in Q4 2025 vs $37.3M loss in Q4 2024; collaboration expense increased to $53.7M.","CASGEVY revenue $54M in Q4, $116M full year 2025; 64 patients infused during the year (30 in Q4).","Cash, cash equivalents and marketable securities $1,975.8M as of Dec 31, 2025, vs $1,903.8M Dec 31, 2024.","R&D expenses $83.5M (Q4 2025) vs $71.7M (Q4 2024); G&A $18.4M vs $18.1M.","Pediatric CASGEVY submissions for ages 5-11 expected H1 2026; in vivo programs CTX460 (mid-2026) and CTX340 (H1 2026) to enter clinic."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-048873","json":"https://secwatch.observer/filing/0001193125-26-048873.json","markdown":"https://secwatch.observer/filing/0001193125-26-048873.md","text":"https://secwatch.observer/filing/0001193125-26-048873.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1674416/000119312526048873/0001193125-26-048873-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1674416/000119312526048873/crsp-20260212.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T03:03:39.140778+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}